Increasing reactive oxygen species as a therapeutic approach to treat hereditary leiomyomatosis and renal cell carcinoma

Keyphrases

• Therapeutic Approaches 100%
• Renal Cell Carcinoma 100%
• Reactive Oxygen Species 100%
• Hereditary Leiomyomatosis 100%
• Hereditary Leiomyomatosis Renal Cell Carcinoma 100%
• Bortezomib 72%
• Inducer 36%
• Cisplatin 27%
• Renal Carcinoma Cells 27%
• Reactive Oxygen Species Level 27%
• Renal Tumor 18%
• Cytotoxic Effect 18%
• Induced Apoptosis 9%
• Tumor 9%
• Cytotoxicity 9%
• Synthetic Lethality 9%
• Protease Inhibitors 9%
• Tumor Cell Death 9%
• Targeted Therapeutics 9%
• Kidney Cancer 9%
• Metastasizing 9%
• High Potency 9%
• Tumor Regression 9%
• Effective Forms 9%
• Tumor Growth in Vivo 9%
• Enhanced Cytotoxicity 9%
• Reactive Oxygen Species Scavenger 9%
• In Vivo Xenograft Model 9%
• Murine Xenografts 9%

Medicine and Dentistry

• Clear Cell Renal Cell Carcinoma 100%
• Reactive Oxygen Species 100%
• Leiomyomatosis 100%
• Bortezomib 66%
• Cytotoxicity 33%
• Carcinoma Cell 25%
• Cisplatin 25%
• In Vitro 16%
• Xenograft 16%
• Kidney Tumour 16%
• Neoplasm 8%
• Tumor Progression 8%
• Programmed Cell Death 8%
• Tumor Cell 8%
• Lethality 8%
• Proteasome Inhibitor 8%
• Kidney Cancer 8%
• Tumor Regression 8%
• Cell Death 8%

Pharmacology, Toxicology and Pharmaceutical Science

• Renal Cell Carcinoma 100%
• Reactive Oxygen Metabolite 100%
• Leiomyomatosis 100%
• Bortezomib 66%
• Cytotoxicity 33%
• Cisplatin 25%
• Neoplasm 16%
• Kidney Tumour 16%
• Tumor Growth 8%
• Lethality 8%
• Tumor Regression 8%
• Proteasome Inhibitor 8%
• Kidney Cancer 8%